Top stock gainers today: premarket & intraday live
Top gainers is the first scanner most day traders open in the morning. It answers the simplest question on the tape: what is going on today, and which names are leading the move.
Leader right now: DCOY +38.70% at $3.53. Sourced from the live 15-min-delayed scanner snapshot above.
// As of September 22, 2026 · delayed 15 min
What's moving the tape on DCOY, grounded in Tapeboard's data. Not investment advice.
As of
- Decoy Therapeutics Announces Its Exploring Non-Dilutive Federal Grants, Public Health Collaborations To Support Preclinical, Clinical Development Of Biodefense Pipeline — Benzinga - Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference — Yahoo
- The company is exploring non-dilutive federal grants and public health collaborations to support its biodefense pipeline. - The recent news suggests that the company is actively seeking partnerships and funding to advance its research.
- The company has a history of significant losses, with a net income of -$12518480 in 2025 and -$5575777 in 2024. - The company's operating expenses have been increasing, with $12613952 in 2025 and $5734316 in 2024.
- The company has a high short interest ratio, with a squeeze score of 9.9 and 0.49 days to cover. - The company's revenue and gross margin are not available in the data.
- The company's future revenue and profitability are uncertain due to the lack of available data. - The company's ability to secure non-dilutive federal grants and public health collaborations is not guaranteed. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on VKTX, grounded in Tapeboard's data. Not investment advice.
As of
- "Weight Loss Drug: Viking Therapeutics Says Lead Obesity Drug Shows Weight Retention with Less Frequent Dosing" (Benzinga) - "Viking Therapeutics Announces Top-line Results From Maintenance Study Of VK2735… 22% Placebo-Adjusted Weight Loss Reported At Week 33" (Benzinga)
- Strong analyst consensus: 9 strong buys, 14 buys across multiple future periods. - High RVOL (28.96x) and day volume 33.2M indicate intense buying interest.
- Recent SeekingAlpha headline: "The Market Might Shrug Off The Maintenance Data" suggests skepticism. - Negative earnings: net income -$0.36B FY2025, EPS -3.19, PE -8.33.
- Squeeze score 34.8/100 (moderate) and days to cover 12.6 signal potential short‑squeeze volatility. - No revenue (SEC shows $0) and continued cash‑flow burn (-$278.7M operating FY2025).
- Exact timing and magnitude of future VK2735 regulatory milestones are not disclosed. - Future dilution risk from potential financing needs given ongoing losses. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on BFLY, grounded in Tapeboard's data. Not investment advice.
As of
- No recent news available in the data - Price up 17.38% on heavy volume (RVOL 4.37x) vs prior close $8.14
- Revenue grew +19% YoY to $0.10B with improving gross margin 46.9% - Analyst estimates consistently show strong buy/buy consensus across multiple periods
- Net income remains negative ($-0.08B) and EPS is negative (-0.31) - Operating cash flow negative (-$12.7M) and free cash flow negative (-$16.0M)
- High price-to-sales ratio (22.5) suggests rich valuation relative to sales - Short interest data limited; easyToBorrow flag is false, indicating potential borrowing constraints
- No forward guidance or upcoming catalysts disclosed in the provided data - Lack of recent news leaves uncertainty about any near‑term operational developments --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on INOD, grounded in Tapeboard's data. Not investment advice.
As of
- "Cerebras Systems vs. Innodata: Which AI-Driven Tech Stock Is a Better Buy in 2026?" — Yahoo - "Innodata's Customer Diversification Effort: Is It Finally Paying Off?" — Yahoo
- Revenue up 47.6% YoY with Q2 2026 EPS surprise of +89.6% and Q1 surprise of +446.9% - Analyst consensus shows 9 strong buys/buys vs 1 hold across multiple 2026 periods
- Stock still down ~47% over the last 3 months per recent headline - P/E ratio ~53 and P/S ~7.6 indicate premium valuation relative to peers
- Short interest days to cover 3.1 with easyToBorrow flag false, suggesting borrowing constraints - Squeeze score low at 19.7/100, limiting short‑squeeze potential
- No clear forward guidance on FY 2027 revenue or margin expansion - Uncertain impact of new board appointment (Admiral Rogers) on federal contract pipeline --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on OMER, grounded in Tapeboard's data. Not investment advice.
As of
- No recent news available in the data - Price up $1.65 (+8.9%) on volume 1.05M, RVOL 2.47x indicating heightened activity
- Shares trading above 52‑week high ($19.65) showing strong upward momentum - Short interest modest (days to cover 5.5, squeeze score 28.9) limiting downside pressure
- FY 2025 net loss of $3.35M and negative EPS (-$0.05) reflect ongoing unprofitability - Negative book value per share (-$0.71) and PB ratio -28.3 signal balance‑sheet weakness
- Operating cash flow negative for FY 2025 (-$116M) and FY 2024 (-$149M) - Easy‑to‑borrow flag false, suggesting potential borrowing constraints for shorts
- No forward guidance or pipeline updates provided in the data - Unclear timing of any potential catalysts driving the current price move --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on SNXX, grounded in Tapeboard's data. Not investment advice.
As of
- "Sandisk Options Surge As SNXX Ranks Among Most Active ETFs. What Investors Are Betting On" – Benzinga - "SNXX: Benefits And Risks Of Leveraging Sandisk Corp." – SeekingAlpha
- Leveraged 2× exposure to Sandisk amplifies upside if the AI‑memory trade continues. - Day volume of 71.7 M shares and RVOL 2.07× show strong trader interest and liquidity.
- Leveraged ETFs suffer from daily reset decay, especially in choppy or sideways markets. - SNXX is not easy to borrow, limiting short‑side flexibility and increasing borrowing costs.
- High volatility: price is only 36% through its 52‑week range, indicating large swings. - No fundamentals (earnings, P/E, etc.) are available for SNXX, making valuation unclear.
- Future direction of Sandisk’s underlying stock and the broader AI memory sector. - How long the current options‑driven buying pressure will persist before a potential reversal. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on BOIL, grounded in Tapeboard's data. Not investment advice.
As of
- BOIL rose 11.71% to $21.75 on heavy volume (RVOL 1.76x) as the day’s top mover. - The sole recent headline: “Time To Trade Natural Gas With The BOIL ETF” (SeekingAlpha) highlights expected volatility in U.S. natural gas futures.
- FY‑2025 SEC filing shows net income of $1.71 B and cash & equivalents of $3.25 B, a strong balance sheet. - The ETF’s leveraged exposure can amplify gains if natural‑gas futures continue to rally.
- Price sits only 5% above the 52‑week low ($18.31) and far below the 52‑week high ($93.70), indicating deep‑value skepticism. - Leveraged ETFs suffer from decay in sideways or choppy markets, eroding returns over time.
- The fund is marked “easyToBorrow: false,” suggesting potential short‑sale constraints and higher borrowing costs. - As a 2× leveraged product, BOIL’s daily rebalancing can lead to significant tracking error versus the underlying index over longer horizons.
- Future direction of U.S. natural‑gas prices and related futures curves, which drive the ETF’s performance. - Scale and timing of investor inflows or outflows that could affect liquidity and price pressure beyond today’s volume spike. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on IBRX, grounded in Tapeboard's data. Not investment advice.
As of
- "Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode" — Yahoo - "IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet" — Yahoo
- Analyst consensus shows 4 strong buys and 5 buys across multiple 2026 periods, indicating broad optimism. - Revenue surged +668.3% YoY (2025) and gross margin is 99.3%, highlighting rapid top‑line growth.
- Net income remains deeply negative (‑$0.35B FY 2025) with EPS of ‑$0.38 and continued operating losses. - Recent earnings surprises were mostly negative, the latest quarter missing estimates by ‑139.6%.
- Short interest is high: 125.6M shares sold short, days to cover 14.7, and the stock sits on the FINRA threshold list (squeeze score 28.1). - Balance sheet shows negative total stockholders’ equity (‑$500.5M) and net debt of ‑$86.6M, reflecting persistent funding pressure.
- Whether the founder’s tokenization tease will materialize into a concrete product or remain speculative. - Timing and outcome of upcoming cancer‑conference presentations and any potential M&A interest from big pharma. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on GRAB, grounded in Tapeboard's data. Not investment advice.
As of
- "Why Is Grab Stock Trading Higher Today?" highlights CEO and COO insider purchases of ~10.65 M shares worth >$30.7 M. - "Grab to Buy 60% of Atome for $1.49B, Raises 2028 Growth Targets" announces a controlling stake in Atome Financial and lifted long‑term guidance.
- Analyst estimates show strong consensus: 10 Strong Buy, 17 Buy, 2 Hold across multiple periods. - Recent earnings surprises were large (+157.5% Q2 2026, +88.7% Q1 2026) and the company completed a share‑repurchase plan.
- The stock sits near the bottom of its 52‑week range (12% of the range) with a high P/S of 3.49, suggesting stretched valuation. - Squeeze score is modest (33.8/100) and days to cover short interest are 6.8, limiting short‑squeeze potential.
- Short interest is 261.65M shares (≈8.7% of float) and the stock is not easy to borrow (easyToBorrow: false). - RVOL is elevated at 3.36×, indicating unusually high trading activity that could reverse quickly.
- How the Atome acquisition will integrate and impact profitability remains unclear. - Broader macro‑economic conditions in Southeast Asia and consumer‑spending trends are not detailed in the data. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on TRLV, grounded in Tapeboard's data. Not investment advice.
As of
- Trulieve Cannabis Announces It Has Been Added To S&P Total Market Index And S&P Completion Index (Benzinga) - Trulieve: As Regulatory Headwinds Wane, Value Creation Is On The Cards (SeekingAlpha)
- Analyst estimates show strong buy/buy consensus (2 strong buy, 10 buy across periods) indicating upside expectation. - Recent quarterly earnings surprise was positive in Q1 2026 (+0.0253 EPS vs -0.0153 estimate) and operating cash flow remains robust (~$272M FY2025).
- Net income is negative for FY2025 (-$122M) and revenue declined slightly YoY (-0.4%). - EPS remains deeply negative (-$0.608) and the P/E ratio is negative (-5.05), reflecting unprofitability.
- Short interest is low (1.44M shares, days to cover 1.4) but squeeze score is weak (13.2/100), limiting short‑squeeze potential. - Stock is not easy to borrow (easyToBorrow: false), which could hinder short‑selling activity and increase borrowing costs.
- No live short‑interest percentage of float is provided, so the true short‑side pressure is unclear. - Forward guidance or upcoming regulatory developments beyond the cited headlines are not detailed in the data. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on SOXL, grounded in Tapeboard's data. Not investment advice.
As of
- No recent news available in the data - Price rose 6.42% to $150.94 on 64.8M shares traded (RVOL 1.08x)
- Leveraged 3× exposure to semiconductor upside amplifies gains if sector momentum continues - Current price sits 45% through its 52‑week range, leaving room for further upside before hitting the high
- As a daily‑reset 3× bull ETF, SOXL suffers from volatility decay in choppy or sideways markets - Easy‑to‑borrow flag is false, indicating potential short‑selling constraints that could exacerbate price swings
- Leveraged structure magnifies both gains and losses; adverse semiconductor moves can lead to rapid drawdowns - No dividend yield to offset volatility (yield ~0.06%) and no fundamentals (PE, EPS) to anchor valuation
- Future direction of semiconductor demand and supply chain dynamics not captured in the data - How long the current intraday momentum will persist before the ETF’s daily reset impacts performance --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on UNG, grounded in Tapeboard's data. Not investment advice.
As of
- Price rose 5.7% to $10.845 on heavy trading (44 M shares, RVOL 2.73×) indicating strong short‑term buying pressure. - No recent news available in the data to explain the move beyond price/volume action.
- The fund reported $34.2 M net income for FY 2025 and holds $438 M cash with modest liabilities ($28.8 M). - Operating cash flow was positive $127 M in the latest fiscal year, showing underlying cash generation.
- TTM EPS is –71.46 and recent quarterly revenues have swung sharply negative (e.g., –$121 M in Q2 2025). - The fund’s price remains well below its 52‑week high ($17.02), suggesting limited upside momentum.
- Shares are shortable but not easy to borrow, which could constrain short‑selling and increase volatility. - The fund’s net income shows large quarter‑to‑quarter swings, exposing investors to earnings volatility. UNKNOWS - Future natural‑gas price trends and demand shifts that drive the fund’s performance are not detailed in the data. - Any upcoming regulatory or macro‑economic events affecting energy markets are unknown from the provided information. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on TLRY, grounded in Tapeboard's data. Not investment advice.
As of
- Tilray Brands, Inc. (TLRY) Laps the Stock Market: Here's Why — Yahoo - Will Tilray Brands Stock Take Off Before the End of 2026? — Yahoo
- Revenue rose 11.5% YoY to $0.92B with gross margin 28.4% (SEC 2026 filing) - Analyst consensus shows 3 strong‑buy and 5 buy ratings across recent periods
- Net income was ‑$0.12B for FY 2026 and EPS ‑1.09, reflecting continued losses - Price sits only 3% into the 52‑week range ($3.67–$23.20), far below peak levels
- Short interest represents ~13.6% of float with 4.5 days to cover and easyToBorrow = false - Squeeze score is low at 23.2/100, indicating limited short‑squeeze potential
- Timing and outcome of any U.S. marijuana rescheduling or federal reform remain unclear - Whether upcoming catalysts (e.g., policy shifts) will translate into sustained earnings improvement is unknown. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on BTG, grounded in Tapeboard's data. Not investment advice.
As of
- BTG rose 2.05% to $5.47 on heavy volume (RVOL 4.32x) as the market digested the "Full Transcript: B2Gold Q2 2026 Earnings Call" (Benzinga). - Day‑trading activity shows strong buying pressure with price up $0.11 from the prior close.
- Valuation looks attractive: P/E ~9.8, P/B ~1.8, and a dividend yield of 1.46% provide income and downside support. - The stock sits 72% through its 52‑week range ($3.56‑$6.21), leaving room for further upside if gold prices stay firm.
- Short‑interest metrics are modest (squeeze score 17.8/100, days to cover ~2.6), limiting short‑squeeze potential. - Shares are not easy to borrow (easyToBorrow: false), which could hinder short‑selling activity and increase borrowing costs.
- Short‑interest data is stale (as of 2026‑08‑31) and lacks a %‑of‑float figure, so current short pressure is uncertain. - The company’s easyToBorrow flag suggests potential liquidity constraints for short positions, adding volatility risk.
- Future gold price outlook and production guidance from the Q2 2026 earnings call are not detailed in the provided snippet. - Any upcoming operational updates, cost‑inflation pressures, or macro‑economic shifts affecting mining stocks remain unspecified. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on INFQ, grounded in Tapeboard's data. Not investment advice.
As of
- "Is This A $20 Million Reason to Buy Infleqtion Stock Now?" highlights a new NASA contract driving today’s gain. - "As Infleqtion Teams Up With Cisco, Here’s How You Should Play INFQ Stock Now" and the NVIDIA CUDA‑Q software advance underscore partnership momentum.
- Analyst estimates show a strong buy/buy consensus across multiple periods (5‑5‑1‑0‑0). - Recent headlines cite a $20 M NASA deal, Cisco collaboration, and NVIDIA‑backed quantum software progress.
- The company posted a net loss of ‑$0.07 B (FY 2025) and negative stockholders’ equity (‑$77.6 M). - Valuation metrics are extreme: P/S ≈ 75×, P/B ≈ 5.5×, and EPS remains deeply negative (‑$0.33 TTM).
- RVOL is only 0.87×, indicating weaker‑than‑average intraday interest. - Squeeze score is low at 17.8/100 and days‑to‑cover ≈ 2.6, limiting short‑squeeze potential.
- Timing and scale of revenue generation from the NASA and Cisco deals remain unspecified. - Cash runway and potential dilution from ongoing financing activities are not detailed in the data. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on OPEN, grounded in Tapeboard's data. Not investment advice.
As of
- Opendoor Gains 5% but Is Still Down 24% in a Month. Will the Bulls or Bears Win? — Yahoo - Rate Hike Jitters Rattle iBuyer Stocks: Opendoor Falls 4%, Zillow Slides 2% but Offerpad Holds Steady — Yahoo
- Recent revenue growth (4.37B in 2025) could support a potential turnaround - Analysts have maintained an Overweight rating on Opendoor Technologies
- Revenue YoY: -15.2% vs prior year - Net income: -$1.30B in 2025, with a net income margin of -30.0%
- Days to cover: 5.1, indicating a relatively high short interest - Squeeze score: 21/100, indicating a potential squeeze in the short position
- No clear catalyst for the recent price increase - Uncertainty surrounding the company's ability to turn around its revenue and net income --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
What's moving the tape on RGTI, grounded in Tapeboard's data. Not investment advice.
As of
- "Trump Admin Launches $215M Quantum Competition: IonQ, D-Wave, Rigetti Take Notice" — Benzinga - "IonQ Climbs 9% on Quantum Optimization Work With NVIDIA; D-Wave Rises 8%, Rigetti Gains 7%" — Yahoo
- Analyst consensus shows 3 strong buys and 11 buys across recent periods. - Recent earnings surprises were positive in three of the last four quarters.
- Company reports negative net income of $-0.22 B (TTM) and a PS ratio of 413. - Operating cash flow remains deeply negative, with FY 2025 free cash flow at $-77 M.
- Short interest days to cover is 3.2, indicating modest bearish pressure. - RVOL is 0.73x, below average trading interest for the time of day.
- No clear timeline for revenue generation or profitability in quantum computing. - Uncertain impact of the $215M federal quantum competition on Rigetti’s market share. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
See this live in the Tapeboard scanner
This table is baked at build time and never moves. The scanner runs the same scan continuously, streaming and filterable, with a chart and research pane one click away on every row. Free, no account needed.
Open the live top gainers scannerWhat are the biggest gainer movers today?
- // Ranked by intraday percent change, live refresh
- // Default minimum daily volume floor at 500K shares to filter illiquid noise
- // Default minimum price filter at $1, configurable
- // News-recency badge on every row to flag fresh catalysts
- // Click-through to a full chart with the catalyst headline visible
- // Streaming real-time. Rows update as prints land, not on a 10-second refresh delay.
- // Click any ticker for the full research pane: chart, Level 2, time & sales, filings, insider activity, news recency.
- // 15-minute delay on the public surface; signed-in users see the live tape without delay.
- // Free to view. No card. No paywall on this page.
Frequently asked questions about today's market movers
// Other movers categories you might want next to this one:
Watch the movers live on Tapeboard.
// 28 sec to first scanner · no card · cancel anytime
Start free View pricing See it live in the scanner